MoonLake (NASDAQ: MLTX) has received a positive assessment from Wedbush analyst Andreas Argyrides, who has maintained an Outperform rating on the stock. Argyrides has also raised the price target for MoonLake from $86 to $92. This indicates a favorable outlook for MoonLake Immunotherapeutics.
Argyrides, a Wall Street analyst at Wedbush, specializes in the General sector and covers a total of 24 stocks. With a success rate of 26.75%, his expertise and analysis carry weight in the industry. He has previously expressed confidence in MoonLake Immunotherapeutics, reaffirming a Buy rating on September 18, 2023.
However, it is important to note that investment decisions should not be solely based on this information. It is advisable to conduct further research and analysis, and seek guidance from a financial advisor before making any investment decisions.
Updated on: 07/12/2023
Debt to equity ratio: Neutral
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
We did not find social sentiment data for this stock
|Analyst / firm||Rating|
MLTX Stock Performance on November 18, 2023: Analysis of Earnings Growth and Volatility
MLTX Stock Performance on November 18, 2023:
On November 18, 2023, MLTX stock displayed an interesting performance. Let’s analyze the key aspects that affected the stock’s performance on that day.
MLTX’s previous close on November 17, 2023, was $40.30. The stock opened at $41.27 on November 18, showing an initial upward movement. Throughout the day, MLTX’s price fluctuated within a range of $40.35 to $43.03, indicating some volatility. The trading volume for the day stood at 56,135 shares, significantly lower than the average volume over the past three months.
MLTX has a market capitalization of $2.0 billion. MLTX’s earnings growth last year was -454.76%, but the company has rebounded this year with earnings growth of +36.65%.
MLTX’s next reporting date is scheduled for March 18, 2024. Analysts forecast an EPS of -$0.29 for the current quarter.
MLTX reported annual revenue of $0.00 last year, suggesting it may be a relatively new player in the pharmaceutical industry. The company recorded an annual profit of -$50.0 million.
MLTX’s P/E ratio is not applicable (NM) due to negative earnings reported in the previous year. The price/sales ratio and price/book ratio are not provided. No competitor data is available.
MLTX’s performance on November 18, 2023, indicates positive momentum in terms of earnings growth. However, investors should closely monitor the company’s financials, especially considering the losses reported in the previous year. Keeping an eye on the pharmaceutical industry as a whole may provide further insights into MLTX’s future performance.
MLTX Stock Shows Positive Performance and Potential for Growth, According to Analysts
MLTX stock had a positive performance on November 18, 2023, based on the information provided by CNN Money. The 9 analysts who offered 12-month price forecasts for MoonLake Immunotherapeutics had a median target of $66.00. The high estimate was $77.00, while the low estimate was $40.00. The median estimate represents a significant increase of 54.39% from the last price of $42.75.
This positive outlook from analysts indicates that there is potential for the stock to experience substantial growth in the coming months.
Furthermore, the current consensus among 13 polled investment analysts is to buy stock in MoonLake Immunotherapeutics. This rating has remained steady since October, indicating a consistent belief in the company’s potential.
Investors should keep an eye on the company’s upcoming reporting date, which is scheduled for March 18. This will provide further insights into the company’s financial performance and may influence the stock’s future performance.
Overall, based on the information provided, MLTX stock had a positive performance on November 18, 2023. The analysts’ forecasts and the consensus among investment analysts suggest that there is potential for significant growth in the stock’s value. However, investors should conduct further research and consider other factors before making any investment decisions.